© Copyright Our Wall
The global endoscopic retrograde cholangiopancreatography (ERCP) devices market is poised for significant growth, with projections indicating a rise to US$ 2.8 billion by 2032, up from US$ 1.5 billion in 2022. This surge is attributed to the escalating incidence of cancer worldwide, as highlighted by industry insights from Future Market Insights (FMI).
ERCP, a vital diagnostic and therapeutic procedure, plays a pivotal role in the management of pancreatobiliary system disorders. It integrates fluoroscopic imaging and luminal endoscopy techniques to diagnose and treat ailments affecting the pancreas and bile ducts. ERCP devices utilize a side-view duodenoscope, navigating through the esophagus, stomach, and into the latter section of the duodenum. These devices enable clinicians to obtain tissue and cell samples, as well as address obstructions in the pancreas or bile duct.
According to FMI's analysis, the sales of ERCP devices are anticipated to grow at a compound annual growth rate (CAGR) of 6.2% from 2022 to 2032. This growth trajectory underscores the increasing demand for advanced medical technologies to address the rising burden of pancreatobiliary disorders.
Get your PDF Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-9658
The duct blockage could be caused by either noncancerous stones or cancer. Imaging tests such as endoscopic retrograde cholangiopancreatography (ERCP) are used to diagnose or examine the pancreatic ducts, gallbladder, liver, and pancreas. Magnetic resonance cholangiopancreatography and computed tomography machines are gradually replacing endoscopic retrograde cholangiopancreatography (ERCP). ERCP devices are used for a variety of procedures such as sphincterotomy, stone removal, stent placement, dilation, and fluid drainage.
Endoscopic Retrograde Cholangiopancreatography (ECRP) Devices Market: Drivers and Restraints-
Endoscopic retrograde cholangiopancreatography (ECRP) devices for cancer treatment have grown in popularity over the years. During the forecast period, the increasing prevalence of benign liver and pancreatic tumours is expected to create appealing market opportunities for endoscopic retrograde cholangiopancreatography (ECRP) devices across regions.
Several ongoing studies for safer use and improved efficiency of these endoscopic retrograde cholangiopancreatography (ECRP) devices, as well as rising government support for R&D, may also drive growth in the endoscopic retrograde cholangiopancreatography (ECRP) device market over the forecast period. Endoscopic retrograde cholangiopancreatography (ECRP) device awareness is expected to drive market growth for ECRP devices, as is increased availability.
High endoscopic retrograde cholangiopancreatography (ECRP) device costs, as well as side effects associated with cholangiopancreatography procedures such as post-ERCP pancreatitis, infection, haemorrhage, and allergic reactions, are expected to stymie market growth for ECRP devices during the forecast period.
Endoscopic Retrograde Cholangiopancreatography (ECRP) Devices Market: Overview
When compared to other endoscopic procedures, endoscopic retrograde cholangiopancreatography (ECRP) devices use advanced techniques, which increases the risk of serious complications. As a result, specialised equipment and training are required, and the procedure is only used in limited circumstances. According to a review by Freeman et al., approximately 500,000 procedures are performed in the United States each year. Endoscopic retrograde cholangiopancreatography (ECRP) devices are commonly used in hospitals for patients suffering from pancreatic or gallstone disease.
Endoscopic Retrograde Cholangiopancreatography (ECRP) Devices Market: Region-wise Outlook
Endoscopic retrograde cholangiopancreatography (ECRP) device sales in North America are expected to skyrocket due to increased diagnostic imaging-related research and improved R&D for advanced and safe ECRP devices. During the forecast period, improved healthcare infrastructure and expenditure are expected to drive the Europe market for endoscopic retrograde cholangiopancreatography (ECRP) devices.
The Asia-Pacific market for endoscopic retrograde cholangiopancreatography (ECRP) devices is expected to grow as cholangiopancreatography procedure awareness grows in China, India, and Japan. The constant increase in the number of ECRP device manufacturers is expected to drive demand for endoscopic retrograde cholangiopancreatography (ECRP) devices during the forecast period.
Endoscopic Retrograde Cholangiopancreatography (ECRP) Devices Market: Key Market Participants
Olympus Corporation, Boston Scientific Corporation, CONMED Corporation, Cook Medical, Inc., Hobbs Medical, Merit Medical Systems, and TeleMed Systems, Inc. are a few market participants identified across the value chain in the global endoscopic retrograde cholangiopancreatography (ECRP) devices market.
Key Segmentation:
By Disease Indication
By Product Type:
By End User:
By Region:
The Wall